SAJID Southern African Journal of Infectious Diseases 2312-0053 2313-1810 AOSIS SAJID-36-209 10.4102/sajid.v36i1.209 Original Research Lack of resistance to macrolides in Mycoplasma genitalium detected in South African pregnant women https://orcid.org/0000-0002-6359-9511 Naicker Meleshni 1 https://orcid.org/0000-0002-0407-4635 Singh Ravesh 2 3 https://orcid.org/0000-0002-5363-9700 Westhuizen Donald van der 4 https://orcid.org/0000-0003-4528-0635 Tinarwo Partson 5 https://orcid.org/0000-0003-2392-0574 Abbai Nathlee S. 6 School of Clinical Medicine Research Laboratory, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa Department of Medical Microbiology, College of Health Sciences, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa Department of Microbiology, National Health Laboratory Services, KwaZulu-Natal Academic Complex, Inkosi Albert Luthuli Central Hospital, Durban, South Africa Inqaba Biotechnical Industries (Pty) Ltd, Pretoria, South Africa Department of Biostatistics, College of Health Sciences, University of KwaZulu-Natal, Nelson R Mandela School of Medicine, Durban, South Africa School of Clinical Medicine Research Laboratory, Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa Corresponding author: Nathlee Abbai, abbain@ukzn.ac.za 15012021 2020 36 1 209 20042020 21092020 © 2021. The Authors 2021 Licensee: AOSIS. This work is licensed under the Creative Commons Attribution License. Background

Azithromycin regimens have been considered first-line treatment for Mycoplasma genitalium (M. genitalium), a sexually transmitted infection (STI) associated with adverse pregnancy outcomes. However, recent years have seen rapid emergence of macrolide resistance in M. genitalium as a result of widespread administration of azithromycin. Currently, there are limited data on macrolide resistance in pregnant women from KwaZulu-Natal (KZN), South Africa. This study investigated the prevalence of M. genitalium and emerging patterns of macrolide resistance in pregnant women from KZN.

 Methods

This was a sub-study of a larger study which involved laboratory-based detection of STIs in pregnant women. In the main study, pregnant women provided urine samples for detection of STIs. For this study, deoxyribose nucleic acid (DNA) extracted from stored urine was used to determine emerging macrolide resistance by amplification of the 23S ribosomal ribonucleic acid (rRNA) gene of M. genitalium by polymerase chain reaction (PCR) and sequencing of amplicons to identify mutations associated with resistance. The Allplex™ MG & AziR assay was used as a confirmatory assay.

 Results

The prevalence of M. genitalium in pregnant women was 5.9% (13 out of 221). Sequencing of PCR amplicons did not reveal the presence of the A2059G and A2058G mutations associated with macrolide resistance. These findings were confirmed by the Allplex™ MG & AziR assay.

 Conclusion

Despite the lack of resistance to macrolides in this study population, continued antimicrobial resistance surveillance for M. genitalium in pregnant women is important because azithromycin is now part of the South African national STI syndromic management guidelines for vaginal discharge syndrome.

 Mycoplasma genitalium pregnant women azithromycin macrolide resistance 23S rRNA gene mutations KwaZulu-Natal Introduction

Mycoplasma genitalium (M. genitalium) is an emerging sexually transmitted infection (STI) that is associated with non-gonococcal urethritis (NGU) in men1,2 and cervicitis in women.2,3 In addition, genital mycoplasma infections in women have been implicated in various pathological conditions and upper genital tract complications during pregnancy, consequently giving rise to a host of adverse outcomes. These include pelvic inflammatory disease, endometritis, chorioamnionitis and postpartum fever, resulting in complications such as infertility, spontaneous abortion, stillbirth, preterm birth, low birth weight and perinatal mortality.4,5,6,7,8,9 However, there is still controversy regarding the role of M. genitalium in adverse pregnancy outcomes.10,11,12 Further, M. genitalium has been reported to be a possible contributing factor for the acquisition and transmission of human immunodeficiency virus (HIV).13,14 The prevalence of M. genitalium infection in women within the general population was reported between 1% and 4% but can reach 10% or higher in STI clinic attendees.15,16,17 In a study conducted in Pretoria, South Africa, in 2012 and 2016, the prevalence of M. genitalium in termination of pregnancy attendees was reported to be 6.0% in 2012 and 7.7% in 2016.18

Current South African Sexually Transmitted Infections Management Guidelines (2015) recommend the administration of a single oral dose (1 g) of azithromycin for the treatment of vaginal discharge syndrome and male urethritis syndrome.19 However, recent years have seen the rapid emergence of macrolide resistance in M. genitalium as a result of this widespread administration of azithromycin.18,20,21,22,23,24,25 The genetic basis for macrolide resistance was reported to be as a result of mutations occurring at positions 2058 and 2059 (E. coli numbering) within the V region of the 23S ribosomal ribonucleic acid (rRNA) gene of M. genitalium.22

To date, there remains limited data available on the emergence of macrolide resistance in pregnant populations from KwaZulu-Natal (KZN). The present study provides data on the lack of macrolide resistance in pregnant women in our setting. In addition, this study provides data on the prevalence of M. genitalium in pregnant women, which is currently lacking in KZN.

 Materials and methods Study population and samples

The study was a sub-study of the larger study which involved laboratory-based detection of STIs in pregnant women (BE214/17). In the main study, pregnant women provided urine samples for detection of STIs. The women were recruited from the King Edward VIII Hospital in Durban, KZN, during the period November 2017 to April 2018. All enrolled women were 18 years and older, willing to provide written informed consent, information on their demographics, sexual behaviour, clinical information and a urine sample to be tested for vaginal infections.

Deoxyribose nucleic acid (DNA) was extracted from the urine using the PureLinkTM Microbiome DNA Purification Kit (ThermoFisher Scientific, Massachusetts, USA) in accordance with the manufacturer’s instructions. Unused DNA was stored at –20 °C. For this sub-study, n = 221 stored DNA samples were used to determine the presence of emerging resistance to macrolides amongst the participants.

 Detection of <italic>Mycoplasma genitalium</italic> from urine

Commercially available primers and probes specific for M. genitalium (Ba04646249_sl) were used with the TaqMan quantitative polymerase chain reaction (qPCR) assay (ThermoFisher Scientific, USA). The assay was run on the Quant Studio 5 Real-time PCR detection system (ThermoFisher Scientific, USA). The PCR was performed in a final reaction volume of 5 µL comprising: 0.25 µL Fluorescein amidite (FAM)-labelled probe and/or primer mix, 1.25 µL Fast Start 4x probe master mix (ThermoFisher, Part No. 4444434), 1.5 µL template DNA and nuclease-free water. Non-template control reactions and positive controls (TaqMan™ Vaginal Microbiota Extraction Control; cat no. A32039, ThermoFisher Scientific, USA) were also included. Amplification was performed at 95 °C for 30 s followed by 45 cycles comprising of denaturation at 95 °C for 3 s and annealing at 60 °C for 30 s. Detection of amplified fluorescent products was carried out at the end of the annealing phase. The raw fluorescent data included the CT mean values, which were automatically generated by the Quant Studio 5 Real-time PCR system software (ThermoFisher Scientific, USA).

 Detection of mutations in the <italic>23S ribosomal ribonucleic acid</italic> gene conferring macrolide resistance Screening assay: Conventional polymerase chain reaction

Macrolide resistance-associated mutations in the 23S rRNA gene were determined for all samples that tested positive for M. genitalium by the TaqMan assay. The unique 147 base pair (bp) region within the 23S rRNA gene of M. genitalium, which flanks mutations found in the V region of the gene, was amplified and sequenced.22 The screening PCR was performed in a final volume of 25 µL and comprised of 12.5 µL Dream Taq (2x) master mix (ThermoFisher Scientific, USA), 1 µL of each (10 µM) primer, 5 µL template DNA and nuclease-free water. Amplification was performed at an initial denaturation of 95 °C for 2 min, followed by 40 cycles of 95 °C for 30 s (denaturation), 54 °C for 1 min (annealing) and 72 °C for 1 min (extension). A final extension step at 72 °C for 5 min was included. Polymerase chain reaction amplicons were separated on 1% gel electrophoresis and visualised using an ultraviolet transilluminator (Gene Genius, SYNGENE, Maryland, USA).

 Deoxyribose nucleic acid sequencing of amplicons

The 147 bp amplicon was sequenced using the Sanger method at Inqaba Biotechnological Industries in Pretoria, South Africa. The amplicons were sequenced using an ABI3500XL genetic analyser and the raw sequence data were edited using Chromas software V2.6.5 (Technelysium, Queensland, Australia) and then subjected to the National Centre for Biotechnology Information’s (NCBI) Basic Local Alignment Search Tool (BLAST) function for identity confirmation of the amplicons. This was followed by a multiple sequence alignment of study samples – V172, V193 and V208 – with strains of known mutations, LA141 (HF572938.1), LA088 (HF572933.1) and LA202 (HF572946.1), and a strain that does not include the mutations, that is, M. genitalium G37 complete genome (L43967.2), using ClustalW (https://www.genome.jp/tools-bin/clustalw).

 <italic>Confirmatory assay – Allplex™ MG & AziR assay</italic> (Seegene)

The Allplex™ MG & AziR assay (Seegene, Seoul, South Korea) is a commercially available assay which allows for the simultaneous detection and identification of M. genitalium and six mutations (A2058C, A2058G, A2058T, A2059C, A2059G and A2059T) responsible for azithromycin resistance on validated sample types, which include genital swabs, urine and liquid-based cytology samples. The testing was performed as per the kit instructions and the samples were run on the Bio-Rad CFX96 equipped with Seegene interpretative software.

 Statistical analyses

The statistical analysis was conducted using R software (version 3.6.1), a freely available software environment for statistical computing. Initially, the population characteristics were described using frequencies stratified by infection status of the STI investigated. All the tests were conducted at 5% level of significance.

 Ethical consideration

Ethical approval to conduct the study was obtained from the Biomedical Research Ethics Committee (BREC), University of KwaZulu-Natal (UKZN), (reference no. BE214/17).

 Results Characteristics of the population according to <italic>Mycoplasma genitalium</italic> status

Out of 221 samples, 13 tested positive for M. genitalium using the TaqMan assay. The prevalence of M. genitalium in the study population was 5.9%. The median age of all 13 of the women who tested positive for M. genitalium was 26 years (interquartile range [IQR] 21–35). The analysis showed no significant associations (p > 0.05) between socio-demographic, behavioural and clinical data with reference to M. genitalium status (Table 1). Despite the lack of statistical significance, more than 60% of the women who tested M. genitalium positive did not present with symptoms of abnormal vaginal discharge on the day of enrolment. Similarly, more than 75% of the women did not experience previous symptoms of STIs 3 months prior to the enrolment. All women who tested positive for M. genitalium (n = 13) were unmarried. More than half of these women (53.8%) had reported having between two and four life-time sexual partners. A larger proportion of the positive women (53.8%) had indicated that either their current sexual partners had no other partners, or they were not aware of their partners having other partners. With regard to behavioural practices, 84.6% of the M. genitalium positive women had not used a condom during their last sexual act. Clinically, the majority of women who tested positive were in the third trimester of pregnancy (53.8%).

Characteristics of the study population stratified by Mycoplasma genitalium status.

Characteristics Mycoplasma genitalium infection
 p
Negative (n = 208)
 Positive (n = 13)
 Overall (n = 221)
n % Mean ± SD Median n % Mean ± SD Median n % Mean ± SD Median
Age - - - - - - - - - - - 0.622
CV - 21.1 28.3 ± 5.97 - - 26.7 28.0 ± 7.47 - - 21.3 28.3 ± 6.04 - -
Q1 28 - - 24.0 26 - - 21.0 27 - - 24.0 -
Q3 - - - 33.0 - - - 35.0 - - - 33.0 -
Minimum–maximum 18.0–43.0 - - - 20.0–42.0 - - - 18.0–43.0 - - - -
Current abnormal vaginal discharge - - - - - - - - - - - - 0.771
No 136 65.4 - - 8 61.5 - - 144 65.2 - - -
Yes 72 34.6 - - 5 38.5 - - 77 34.8 - - -
Symptoms of STIs in the past 3 months - - - - - - - - - - - - 0.428
No 177 85.1 - - 10 76.9 - - 187 84.6 - -
Yes 31 14.9 - - 3 23.1 - - 34 15.4 - -
Level of education - - - - - - - - - - - - 0.139
Primary and below 13 06.2 - - 2 15.4 - - 15 06.8 - - -
High school 140 67.3 - - 6 46.2 - - 146 66.1 - - -
College/University 55 26.4 - - 5 38.5 - - 60 27.1 - - -
Marital status - - - - - - - - - - - - 0.223
No 175 84.5 - - 13 100 - - 188 85.5 - - -
Yes 32 15.5 - - 0 0.0 - - 32 14.5 - - -
Has a regular sexual partner - - - - - - - - - - - - 0.703
No 37 17.8 - - 1 07.7 - - 38 17.2 - - -
Yes 171 82.2 - - 12 92.3 - - 183 82.8 - - -
Living with sexual partner - - - - - - - - - - - - 0.24
No 126 60.6 - - 10 76.9 - - 136 61.5 - - -
Yes 82 39.4 - - 3 23.1 - - 85 38.5 - - -
Age at first sex - - - - - - - - - - - - 0.158
< 15 9 04.3 - - 2 15.4 - - 11 05.0 - - -
15–20 156 75.0 - - 10 76.9 - - 166 75.1 - - -
> 20 43 20.7 - - 1 07.7 - - 44 19.9 - - -
Life-time number of sexual partners - - - - - - - - - - - - 0.933
1 57 27.4 - - 4 30.8 - - 61 27.6 - - -
2–4 106 51.0 - - 7 53.8 - - 113 51.1 - - -
> 4 45 21.6 - - 2 15.4 - - 47 21.3 - - -
Partner has other partners - - - - - - - - - - - - 0.215
No/don’t know 148 71.2 - - 7 53.8 - - 155 70.1 - - -
Yes 60 28.8 - - 6 46.2 - - 66 29.9 - - -
Condom use - - - - - - - - - - - - 1
Never/rarely 72 34.6 - - 4 30.8 - - 76 34.4 - - -
Sometimes/always 136 65.4 - - 9 69.2 - - 145 65.6 - - -
Condom use at last sexual act - - - - - - - - - - - - 0.23
No 138 66.3 - - 11 84.6 - - 149 67.4 - - -
Yes 70 33.7 - - 2 15.4 - - 72 32.6 - - -
Smokes - - - - - - - - - - - - 0.091
No 201 96.6 - - 11 84.6 - - 212 95.9 - - -
Yes 7 03.4 - - 2 15.4 - - 9 04.1 - - -
Consumes alcohol - - - - - - - - - - - - 0.631
No 187 89.9 - - 11 84.6 - - 198 89.6 - - -
Yes 21 10.1 - - 2 15.4 - - 23 10.4 - - -
Intravaginal practices - - - - - - - - - - - - 1
No 188 90.4 - - 12 92.3 - - 200 90.5 - - -
Yes 20 09.6 - - 1 07.7 - - 21 09.5 - - -
Trimester of pregnancy - - - - - - - - - - - - 0.175
First 18 08.7 - - 3 23.1 - - 21 9.5 - - -
Second 72 34.6 - - 3 23.1 - - 75 33.9 - - -
Third 118 56.7 - - 7 53.8 - - 125 56.6 - - -
Previous preterm delivery - - - - - - - - - - - - 1
No 165 81.3 - - 11 84.6 - - 176 81.5 - - -
Yes 38 18.7 - - 2 15.4 - - 40 18.5 - - -
Past miscarriage - - - - - - - - - - - - 0.193
No 150 72.1 - - 12 92.3 - - 162 73.3 - - -
Yes 58 27.9 - - 1 07.7 - - 59 26.7 - - -
Past spontaneous abortion - - - - - - - - - - - - 1
No 189 90.9 - - 12 92.3 - - 201 91.0 - - -
Yes 19 9.1 - - 1 07.7 - - 20 09.0 - - -
Previous abnormal vaginal discharge - - - - - - - - - - - - 0.774
No 119 57.2 - - 8 61.5 - - 127 57.7 - - -
Yes 88 42.3 - - 5 38.5 - - 93 42.3 - - -
Previously treated for STIs - - - - - - - - - - - - 0.839
No 118 56.7 - - 7 53.8 - - 125 56.6 - - -
Yes 90 43.3 - - 6 46.2 - - 96 43.4 - - -

STI, sexually transmitted infection; CV, coefficient of variation.

 Detection of macrolide resistance-associated mutations in the <italic>23S</italic> ribosomal ribonucleic acid gene Screening assay: Conventional polymerase chain reaction

The 147 bp fragment associated with the 23S rRNA gene was detected in 8 out of 13 (61.5%) of the M. genitalium positive isolates analysed. Sanger sequencing confirmed that the PCR amplicons obtained were the 23S rRNA gene from M. genitalium (Accession number: Mk411362.1). Samples which produced good sequencing reads were aligned with strains with known mutations as well as a strain which lacked the mutations. According to the multiple sequence alignment, positions of known mutations associated with macrolide resistance, that is, A2058G, A2059C and A2059G, were not present in the study samples analysed. Similarly, these mutations were not present in the G37 strain (strain lacking the mutations) (Figure 1). However, as expected, the A2058G mutation was present in strain LA141, the A2059G mutation was present in strain LA088 and the A2059C mutation was present in strain LA202 (Figure 1). The prevalence of macrolide resistant M. genitalium in our study population was 0%.

Multiple sequence alignment of study samples (V172, V193 and V208) with strains of known mutations, LA141 (HF 572938.1), LA088 (HF 572933.1) and LA202 (HF 572946.1), and strain G37, which lacks the mutations.

 Confirmatory assay – Allplex™ MG & AziR assay (Seegene)

The Allplex™ MG & AziR assay produced results for 11 out of 13 samples tested (84.61%) showing that it is much more sensitive than the screening assay (conventional PCR). The conventional PCR detected the 23S rRNA in 61.5% of the samples tested (Table 1-A1). Two of the study samples V014 and V069 did not produce a positive result for the presence of M. genitalium on the Allplex™ MG & AziR assay despite testing positive on the TaqMan assay and yielding the 147 bp amplicon. The discrepancy between the assays may have been the result of loss of sample integrity (as a result of the freeze-thawing process) or loss of sample volume during shipment.

However, the Allplex™ MG & AziR assay confirmed that the prevalence of macrolide resistant M. genitalium in our study population was 0%. None of the study samples tested positive for any of the six mutations (A2058C, A2058G, A2058T, A2059C, A2059G and A2059T) responsible for azithromycin resistance (Table 2-A1). However, all assay controls yielded the expected results indicating that the results were valid.

 Discussion

To the best of our knowledge, this is the first study to provide an estimate on the prevalence of M. genitalium in pregnant women from the Durban area in KZN, South Africa. We report a prevalence estimate of 5.9% for M. genitalium. Our data are consistent with previous reports on M. genitalium infection in South African pregnant women.18,26 Redelinghuys et al. (2013) reported a prevalence of 14.5% for M. genitalium in pregnant women from Gauteng, South Africa.26 Similarly, another study conducted by Le Roux et al. (2018) reported a prevalence of 6.0% in 2012 and 7.7% in 2016 for M. genitalium in pregnant women from Pretoria, South Africa.18 In our study, the factors that could be attributed to this prevalence are as follows: 67.4% of the study women did not use condoms during their last sexual act; 61.5% were not living with their regular partner; 70.1% were unaware if their partner had other partners and 75.1% had first experienced sex between 15 and 20 years of age. In addition, 51.1% had between two and four life-time sex partners and 43.4% were previously treated for STIs. Many of these factors have been shown to contribute to the prevalence of sexually acquired infections.27,28,29,30

The emergence of macrolide resistance in M. genitalium has drawn recent attention.18,20,21,22,23 The first study to report on macrolide resistance in M. genitalium in South Africa was conducted by Hay et al. in the Limpopo province of rural South Africa in 2015.20 In that study, the authors reported detecting macrolide resistance-associated mutations in 4 out of 41 (9.8%) of M. genitalium positive isolates obtained from women attending a primary health care clinic. In contrast, in the current study, no macrolide resistance-associated mutations for the M. genitalium positive samples were reported. Our results are similar to that obtained in a more recent study conducted in Johannesburg, South Africa by Muller et al. (2019). In that study, no macrolide resistance-associated mutations were observed in their total study population of 266 stored M. genitalium positive isolates collected through the Gauteng STI National Microbiological Surveillance programme during the period 2007–2014.21 Similarly, Le Roux et al. (2018) reported no patterns of macrolide resistance amongst their M. genitalium positive isolates obtained in 2012 from pregnant women in Pretoria, South Africa.18 However, in that same study, the authors reported a macrolide resistance-associated mutation (A2059G) amongst their M. genitalium positive isolates obtained in 2016. The same mutation was present in 25% of their isolates tested. There is a possibility that the A2059G mutation is prevalent in South African populations; however, this needs further investigation to provide conclusive evidence.

Despite the lack of resistance to macrolides in the studied population, continued antimicrobial resistance surveillance for M. genitalium in pregnant women will be important since azithromycin is now part of the South African national STI syndromic management guidelines for vaginal discharge syndrome.

The present study was limited in that samples were collected from pregnant women attending a single antenatal facility. However, the hospital from which the women were sampled in this study serves as a central hospital for women from around the Durban area, thereby making the population more generalised. The strength of this study is that we now provide prevalence data as well as data on macrolide susceptibility of M. genitalium in a population of pregnant women from KZN, an area of research that has received limited attention.

 Acknowledgements

The authors thank all study participants as well as the antenatal clinic staff at the King Edward VIII Hospital, Durban.

Competing interests

The authors declare that they have no financial or personal relationships which may have inappropriately influenced them in writing this article.

 Authors’ contributions

All authors contributed equally to the work.

 Funding information

The authors gratefully acknowledge the financial support from the National Research Foundation (Grant number 112080: Awarded to Dr Nathlee S. Abbai).

 Data availability statement

The data that support the findings of this study are available from the corresponding author, upon reasonable request.

 Disclaimer

The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of any affiliated agency of the authors.

 References Jensen JS. Mycoplasma genitalium: The aetiologic agent of urethritis and other sexually transmitted diseases. J Eur Acad Dermatol Venereol. 2004;18(1):1–11. https://doi.org/10.1111/j.1468-3083.2004.00923.x Manhart LE, Critchlow CW, Holmes KK, et al. Mucopurulent cervicitis and Mycoplasma genitalium. J Infect Dis. 2003;187(4):650–657. https://doi.org/10.1086/367992 Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: From Chrysalis to multi-coloured butterfly. Clin Microbiol Rev. 2011;24(3):498–514. https://doi.org/10.1128/CMR.00006-11 Cassell GH, Waites KB, Watson HL, Crouse DT, Harasawa R. Ureaplasma urealyticum intrauterine infection: Role in prematurity and disease in newborns. Clin Microbiol Rev. 1993;6(1):69–87. https://doi.org/10.1128/CMR.6.1.69 Taylor-Robinson D, Furr PM. Update on sexually transmitted mycoplasmas. Lancet. 1998;351(Suppl 1):S12–S15. https://doi.org/10.1016/S0140-6736(98)90004-6 Daxboeck F, Zitta S, Stadler M, Iro E, Krause R. Mycoplasma hominis and Ureaplasma urealyticum in patients with sterile pyuria. J Infect. 2005;51(1):54–58. https://doi.org/10.1016/j.jinf.2004.06.010 Patai K, Szilágyi, G, Hubay, M, Szentmáriay, IF, Paulin, F. Severe endometritis caused by genital mycoplasmas after caesarean section. J Med Microbiol. 2005;54(12):1249–1250. https://doi.org/10.1099/jmm.0.05457-0 Witt A, Berger A, Gruber CJ, et al. Increased intrauterine frequency of Ureaplasma urealyticum in women with preterm labor and preterm premature rupture of the membranes and subsequent cesarean delivery. Am J Obstet Gynecol. 2005;193(5):1663–1669. https://doi.org/10.1016/j.ajog.2005.03.067 Pararas MV, Skevaki CL, Kafetzis, DA. Preterm birth due to maternal infection: Causative pathogens and modes of prevention. Eur J Clin Microbiol Infect Dis. 2006;25(1):562–569. https://doi.org/10.1007/s10096-006-0190-3 Hitti J, Garcia P, Totten P, Paul K, Astete S, Holmes KK. Correlates of cervical Mycoplasma genitalium and risk of preterm birth among Peruvian women. Sex Trans Dis. 2010;37(2):81. https://doi.org/10.1097/OLQ.0b013e3181bf5441 Choi SJ, Park SD, Jang IH, Uh Y, Lee A. The prevalence of vaginal microorganisms in pregnant women with preterm labor and preterm birth. Ann Lab Med. 2012;32(3):194–200. https://doi.org/10.3343/alm.2012.32.3.194 Lis R, Rowhani-Rahbar A, Manhart LE. Mycoplasma genitalium infection and female reproductive tract disease: A meta-analysis. Clin Infect Dis. 2015;61(3):418–426. https://doi.org/10.1093/cid/civ312 Mavedzenge SN, Van Der Pol, B, Weiss, HA, et al. The association between Mycoplasma genitalium and HIV-1 acquistion in African women. AIDS. 2012;26(5):617–624. https://doi.org/10.1097/QAD.0b013e32834ff690 Vandepitte J, Weiss HA, Bukenya J, et al. Association between Mycoplasma genitalium infection and HIV acquisition among female sex workers in Uganda: Evidence from a nested case-control study. Sex Transm Infect. 2014;90(7):545–549. https://doi.org/10.1136/sextrans-2013-051467 Anderson B, Sokolowski I, Ostergaard L, Kjolseth Moller J, Olesen F, Jensen JS. Mycoplasma genitalium: Prevalence and behavioural risk factors in the general population. Sex Transm Infect. 2007;83(3):237–241. https://doi.org/10.1136/sti.2006.022970 Weinstein SA, Stiles BG. A review of the epidemiology, diagnosis and evidence-based management of Mycoplasma genitalium. Sex Health. 2011;8(2):143–158. https://doi.org/10.1071/SH10065 Cazanave C, Manhart LE, Bebear C. Mycoplasma genitalium, an emerging sexually transmitted pathogen. Med Mal Infect. 2012;42(9):381–392. https://doi.org/10.1016/j.medmal.2012.05.006 Le Roux, MC, Mafunise, M, De Villiers, BE, Ditsele, RM. Antimicrobial susceptibility of Mycoplasma genitalium isolates from Pretoria, South Africa in 2012 and 2016. S Afr J Infect Dis. 2018;33(2):46–49. https://doi.org/10.4102/sajid.v33i2.17 Sexually Transmitted Infections Management Guidelines 2015. Adapted from: Standard treatment guidelines and essential drugs list PHC [homepage on the Internet] [cited 2019 Nov 24]. Available from: http://www.kznhealth.gov.za/family/STI-guidelines-2015.pdf Hay B, Dubbink JH, Ouburg S, et al. Prevalence and macrolide resistance of Mycoplasma genitalium in South African women. Sex Transm Dis. 2015;42(3):140–142. https://doi.org/10.1097/OLQ.0000000000000246 Muller EE, Mahlangu MP, Lewis DA, Kularatne RS. Macrolide and fluoroquinoline resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007–2014. BMC Infect Dis. 2019;19(1):148. https://doi.org/10.1186/s12879-019-3797-6 Jensen JS, Bradshaw CS, Tabrizi SN, Fairley CK, Hamasuna R. Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. Clin Infect Dis. 2008;47(12):1546–1553. https://doi.org/10.1086/593188 Manhart LE, Broad JM, Golden MR. Mycoplasma genitalium: Should we treat and how? Clin Infect Dis. 2011;53(Suppl 3):S129–S42. https://doi.org/10.1093/cid/cir702 Manhart LE, Gillespie CW, Lowens MS, et al. Standard treatment regimens for nongonococcal urethritis have similar but declining cure rates: A randomized controlled trial. Clin Infect Dis. 2013;56(7):934–942. https://doi.org/10.1093/cid/cis1022 Bissessor M, Tabrizi SN, Twin J, et al. Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens. Clin Infect Dis. 2015;60(8):1228–1236. https://doi.org/10.1093/cid/ciu1162 Redelinghuys MJ, Ehlers MM, Dreyer AW, Lombaard HA, Kock MM. Prevalence of genital mycoplasmas and bacterial vaginosis in pregnant women in Gauteng, South Africa. Sex Transm Infect. 2013;89(Suppl 1):A159. https://doi.org/10.1136/sextrans-2013-051184.0495 Abbai NS, Wand H, Ramjee G. Sexually transmitted infections in women participating in a biomedical intervention trial in Durban: Prevalence, coinfections, and risk factors. J Sex Trans Dis. 2013;2013:article 358402. https://doi.org/10.1155/2013/358402 Naidoo S, Wand, H, Abbai, NS, Ramjee, G. High prevalence and incidence of sexually transmitted infections among women living in KwaZulu-Natal, South Africa. AIDS Res Ther. 2014;11(1):article 31:1–7. https://doi.org/10.1186/1742-6405-11-31 Abbai NS, Wand H, Ramjee G. Socio-demographic and behavioural characteristics associated with HSV-2 sero-prevalence in high risk women in KwaZulu-Natal. BMC Res Notes. 2015;8:article 185:1–5. https://doi.org/10.1186/s13104-015-1093-0 Abbai NS, Nyirenda M, Naidoo S, Ramjee G. Prevalent herpes simplex virus-2 increases the risk of incident bacterial vaginosis in women from South Africa. AIDS Behav. 2018;22(1):2172–2180. https://doi.org/10.1007/s10461-017-1924-1 Appendix 1

Data from the sensitivity analysis of the 23S ribosomal ribonucleic acid conventional polymerase chain reaction when compared to the AziR assay (comparator assay) computed using R software (version 3.6.1).

AziR assay (comparator assay): Explanation 23S PCR
Element Estimate Lower Upper
Apparent (test or predicted) prevalence (+) APREV 0.615 0.316 0.861
True (outcome) prevalence (+) TPREV 0.846 0.546 0.981
Sensitivity (correct [+] in diseased) SE 0.545 0.234 0.833
Specificity (correct [−] in not diseased) SP 0.000 0.000 0.842
Diagnostic accuracy (total correct [+] and [−]) DIAG.ACC 0.462 0.192 0.749
Diagnostic OR (likely correct [+] in diseased) DIAG.OR 0.000 0.000 -
Number needed to diagnose (to give one [+]) NND −2.200 −1.305 1.483
Youden’s index (max true [+] without false [+]) YOUDEN −0.455 −0.766 0.674
PPV (genuinely diseased in [+]) PPV 0.750 0.349 0.968
NPV (genuinely not diseased in [−]) NPV 0.000 0.000 0.522
LR+ (true [+] to one false [+]) PLR 0.545 0.318 0.936
LR- (false [−] to 10 true [−]) NLR - - -
Proportion of subjects with the outcome ruled out PRO 0.385 0.139 0.684
Proportion of subjects with the outcome ruled in PRI 0.615 0.316 0.861
Proportion of false (+) PFP 1.000 0.158 1.000
Proportion of false (−) PFN 0.455 0.167 0.766
Agreement beyond one expected by chance alone KAPPA −0.282 −0.736 0.173
Dichotomous correlation PHI −0.200 - -
Equivalent continuous scale correlation TETRACHORIC −0.386 - -
Non and diseased discrimination ability (z-score) D’PRIME −0.727 - -
Human interpretation bias CRITERION −0.842 - -
Average sensitivity for all specificity values AUC 0.304 - -
Test for presence of bias (systematic difference) MCNEMAR p = 0.257 - -

PCR, polymerase chain reaction; PPV, positive predictive value; NPV, negative predictive value; APREV, apparent prevalence; TPREV, true prevalence; DIAG.ACC, diagnostic accuracy; DIAG.OR, diagnostic odds ratio; PLR, positive log ratio; NLR, negative log ratio; SE, sensitivity; SP, specificity; NND, number needed to diagnose; PRO, proportion ruled out; PRI, proportion ruled in; PFP, proportion of false positives; PFN, proportion of false negatives; AUC, Area under the curve.

Data obtained for the clinical samples using the Allplex™ MG & AziR assay (Seegene): Output obtained directly from the Seegene viewer linked to the Bio-Rad CFX96 instrument.

Well Name Type FAM
 HEX
 Cal Red 610
 Quasar 670
 Quasar 670
 Auto Interpretation
A2059T C(t) A2058T C(t) A2058C C(t) A2058G C(t) A2059C C(t) A2059G C(t) MG C(t) IC C(t)
A01 V014 SAMPLE − N/A − N/A − N/A − N/A − N/A − N/A − N/A + 29.32 −
B01 V019 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 37.12 + 26.19 MG
C01 V055 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 34.90 + 26.72 MG
D01 V069 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA − N/A + 28.60 −
E01 V083 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 35.71 + 28.31 MG
F01 V103 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 32.07 + 25.13 MG
G01 V104 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 30.11 + 25.00 MG
H01 V109 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 34.57 + 25.64 MG
A12 V193 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 26.33 + 25.07 MG
B12 V172 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 26.25 + 22.96 MG
C12 V197 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 37.96 + 22.97 MG
D12 V208 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 26.50 + 23.59 MG
E12 V238 SAMPLE − N/A − N/A − N/A − N/A − N/A − NIA + 35.29 + 27.30 MG
F12 PC PC + 26.75 + 23.07 + 23.46 + 22.59 + 23.05 + 22.13 + 20.20 + 24.70 Positive Control(+)
G12 NC NC − N/A − N/A − N/A − N/A − N/A − N/A − N/A − N/A Negative Control(−)

N/A, not applicable; FAM, fluorescein amidite; HEX, hexachlorofluorescein; PS, positive control; NC, negative control.

How to cite this article: Naicker M, Singh R, Van der Westhuizen D, Tinarwo P, Abbai NS. Lack of resistance to macrolides in Mycoplasma genitalium detected in South African pregnant women. S Afr J Infect Dis. 2021;36(1), a209. https://doi.org/10.4102/sajid.v36i1.209